Meet our Trustee: Vanessa Forster
Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.
Search results
Vanessa is the General Counsel at the Alan Turing Institute, the UK’s national data science and artificial intelligence research institute.
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Fundraising for Retina UK means a lot to me - both my dad and my nephew have been affected by inherited sight-loss, and I've seen first-hand the incredible work this charity does.
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
A new approach to treating inherited sight loss
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.